324 related articles for article (PubMed ID: 24914821)
1. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
[TBL] [Abstract][Full Text] [Related]
2. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
4. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
5. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
[TBL] [Abstract][Full Text] [Related]
6. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
[TBL] [Abstract][Full Text] [Related]
7. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
[TBL] [Abstract][Full Text] [Related]
9. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
[TBL] [Abstract][Full Text] [Related]
10. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
11. A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation.
Mawatari M; Isoda A; Miyazawa Y; Sawamura M; Matsumoto M
Transpl Infect Dis; 2015 Aug; 17(4):544-50. PubMed ID: 26041667
[TBL] [Abstract][Full Text] [Related]
12. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
[TBL] [Abstract][Full Text] [Related]
14. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
15. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
Rogers JE; Cumpston A; Newton M; Craig M
Transpl Infect Dis; 2011 Oct; 13(5):480-4. PubMed ID: 21615848
[TBL] [Abstract][Full Text] [Related]
16. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
[TBL] [Abstract][Full Text] [Related]
17. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
18. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors.
Kang JM; Kim YJ; Kim JY; Cho EJ; Lee JH; Lee MH; Lee SH; Sung KW; Koo HH; Yoo KH
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1091-8. PubMed ID: 25708217
[TBL] [Abstract][Full Text] [Related]
19. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
Kim DH; Kumar D; Messner HA; Minden M; Gupta V; Kuruvilla J; Chae YS; Sohn SK; Lipton JH
Clin Transplant; 2008; 22(6):770-9. PubMed ID: 18707605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
